Compounded Semaglutide Dosing: A Practical Reference is best understood as a clinical decision topic, not a shortcut. The evidence, pharmacy source, dose plan, contraindications, and follow-up matter more than any single success story online.
A patient I spoke with earlier this year, a 46-year-old dental hygienist named Laura in suburban Phoenix, told me she’d been googling “semaglutide dose chart” for three weeks before she finally enrolled in a compounded program. She had screenshots from Reddit, a PDF from a weight loss clinic in Florida, and a TikTok saved to her favorites showing someone drawing up 0.5 mL from a vial. “I still didn’t know what milligram I was supposed to be on,” she said. That confusion is common, and it’s completely reasonable given how many conflicting references exist online. This article is an attempt to lay out what actually matters.
The Titration Schedule and Why It’s Built That Way
The standard dosing ladder for semaglutide, whether brand-name Wegovy or a compounded preparation, follows a five-rung escalation: 0.25 mg weekly for four weeks, 0.5 mg for four weeks, 1.0 mg for four weeks, 1.7 mg for four weeks, and then 2.4 mg as the maintenance target. That full climb takes roughly sixteen weeks.
This isn’t a formality. GLP-1 receptor agonists slow gastric emptying and suppress appetite through hypothalamic signaling, and both of those effects are dose-dependent. Crank the dose too fast and the GI side effects (nausea, mostly, plus vomiting and diarrhea) become intolerable. And intolerable side effects are the number one reason people quit during the first couple of months. The titration schedule is protective. It’s the difference between easing into a cold pool and cannonballing.
A few practical notes that come up constantly:
Milligrams, not volume. Compounded preparations vary in concentration. One pharmacy might put 5 mg/mL in the vial; another might compound at 2.5 mg/mL. The volume you draw into the syringe changes, but your dose in milligrams should match the schedule. If you’re switching pharmacies or programs mid-titration, confirm the milligram dose, not the tick marks on the syringe.
Same day each week. Pick a day and stick with it. Semaglutide’s half-life supports once-weekly dosing, but weekly consistency keeps the steady-state concentration where it should be. Time of day matters less than calendar-day consistency.
Missed doses. If you remember within about 48 hours of your scheduled shot, take it that day and resume your regular schedule. If more than 48 hours have gone by, skip it entirely and take the next one on your normal day. Don’t double up.
Dose changes belong to your clinician. This sounds obvious but it needs saying. Adjusting your own dose based on what you’ve read online or how your neighbor is doing is a bad idea. Tell your prescribing program before you change anything.
What the Clinical Trials Actually Showed
The dosing schedule above was born from Novo Nordisk’s STEP trial program, and the results are worth knowing because they set expectations.
STEP-1 randomized 1,961 adults with overweight or obesity (no diabetes) to either weekly semaglutide 2.4 mg or placebo for 68 weeks, with lifestyle counseling in both arms. The semaglutide group lost approximately 14.9% of their body weight on average, versus 2.4% in placebo (Wilding et al., New England Journal of Medicine, 2021). Individual responses varied widely, which is the reality with any weight-management medication. Some participants lost more than 20%; others landed closer to 5%.
STEP-3 layered in intensive behavioral therapy and saw a directionally similar, slightly larger effect. STEP-5 ran for 104 weeks and showed the weight reduction was sustained in the active arm, an important data point for anyone wondering whether this is a “stay on it forever” situation (more on that below). STEP-2 focused on adults with type 2 diabetes and obesity, and STEP-4 explored what happens when you withdraw the drug after reaching maintenance.
Separately, the SUSTAIN program tested semaglutide at the diabetes dose range (0.5 mg, 1.0 mg, and later 2.0 mg via SUSTAIN FORTE) in adults with type 2 diabetes. SUSTAIN-6 (Marso SP et al.) was the cardiovascular outcomes trial and showed a reduction in major adverse cardiovascular events in a high-risk diabetes population.
The takeaway for dosing: the dose-response curve is graded. Higher doses produce more weight loss and more glycemic improvement, but also more side-effect burden. That tradeoff is the whole reason the ladder exists.
Mechanism in Plain Language
Semaglutide mimics a hormone your gut already makes called GLP-1. When you eat, intestinal L-cells release GLP-1. It tells your pancreas to produce insulin (only when blood sugar is actually elevated, which is why hypoglycemia is rare on monotherapy), tells your liver to dial back glucagon, slows the speed at which your stomach empties food into the small intestine, and signals appetite-regulating regions in the hypothalamus to quiet down.
The drug version has been engineered with a long half-life, about seven days, so it works as a once-weekly injection rather than requiring constant dosing. That engineering is what makes the weekly schedule possible.
In practice, what patients notice is that they feel full sooner, think about food less often, and lose the “food noise” many describe as a constant low-grade preoccupation with eating. Those subjective reports line up with the central nervous system effects seen in imaging and pharmacology studies.
Side Effects: The Boring Truth
The dominant side effects are gastrointestinal. Nausea, constipation, diarrhea, vomiting, and abdominal discomfort were reported across both the STEP and SUSTAIN programs and show up reliably in real-world cohorts. Most of these are mild to moderate, concentrated in the first eight to twelve weeks, and tend to fade as the body adjusts or as dose stabilization occurs. They’re also the main reason the titration schedule exists in the first place: slow escalation means fewer GI problems.
Less common but more serious events to know about:
- Gallbladder problems, particularly in people losing weight rapidly. Right upper quadrant pain after meals or jaundice warrants prompt evaluation.
- Acute pancreatitis. Rare but real. Severe abdominal pain radiating to the back, especially with fever, means call your clinician immediately.
- Thyroid C-cell tumors. Rodent studies showed a signal. This has not been replicated in humans, but the Wegovy and Ozempic labels carry a boxed warning and a hard contraindication for patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Hypoglycemia on semaglutide alone, in a non-diabetic patient, is uncommon because the insulin effect is glucose-dependent. If you’re also taking insulin or a sulfonylurea for diabetes, the risk goes up, and those medications usually need dose adjustment when semaglutide is added.
I think the most important safety message is this: the titration schedule is your primary tool for managing early side effects. If 0.5 mg is making you miserable, staying at 0.5 mg for an extra four weeks (or dropping back to 0.25 mg temporarily) is a perfectly reasonable clinical decision. Pushing through misery is not a virtue here.
Cost, Supply Pathways, and What “Compounded” Means
Brand-name Wegovy and Ozempic carry a list price above $1,300 per month in the United States. Cash-pay rates at most retail pharmacies land in the $1,000 to $1,400 range. Insurance coverage for the weight-management indication is inconsistent. The diabetes indication has somewhat better coverage but still varies by plan.
Compounded semaglutide is a different supply pathway. The active ingredient is the same, but the preparation is made by state-licensed or 503A compounding pharmacies for individual patients based on a prescriber’s order. HealthRX, as one example, prices its compounded semaglutide program at $179.99 to $279.99 per month depending on dose, covers 44 US states, and operates under LegitScript certification.
The cost difference is real and it’s structural. Brand-name products carry the cost of large-scale clinical development, FDA submissions, post-marketing surveillance, commercial distribution, and profit margins that fund the next wave of R&D. Compounded preparations are produced at a different scale, through a different regulatory framework, at a fundamentally different cost structure.
Where this needs to be said clearly: compounded semaglutide preparations are not FDA-approved as finished products. The clinical evidence from the STEP and SUSTAIN programs was generated using the brand-name product, so the data informs your expectations for compounded versions but doesn’t directly extend to them. The manufacturing oversight model is different (state pharmacy boards and, for 503B outsourcing facilities, a separate FDA framework). Adverse-event surveillance is less systematic.
None of that means compounded semaglutide is unsafe by default. It means the two pathways have different regulatory structures, and an honest reference should name that instead of pretending the distinction doesn’t exist.
For a patient-readable reference covering the dosing schedule, mechanism, and safety framework in more detail: https://healthrx.com/blog/semaglutide-dosing-schedule
HSA and FSA reimbursement for compounded programs depends on your specific plan and how the program invoices. Worth confirming before you enroll.
When to Call Your Clinician (Not Google)
A few scenarios where self-management is the wrong move:
- Severe, persistent abdominal pain, especially radiating to the back or accompanied by fever.
- Inability to keep fluids down for more than 24 hours, signs of dehydration, or persistent vomiting.
- New gallbladder symptoms (right upper quadrant pain after eating, jaundice).
- Reflux that doesn’t improve with meal-timing changes.
- New or worsening mood changes, including depressive symptoms.
- Pregnancy, planned pregnancy, or breastfeeding (this conversation happens before your next dose).
- Personal or family history of medullary thyroid carcinoma or MEN2 that wasn’t discussed at intake. If it wasn’t, raise it now.
- Hypoglycemic episodes if you’re on insulin, sulfonylureas, or other glucose-lowering medications.
- You’re on warfarin or another narrow-therapeutic-window drug and wondering whether slowed gastric emptying could affect absorption. (It might. Ask.)
Frequently Asked Questions
Can I skip a titration step? Skipping steps isn’t standard practice. The schedule exists to let your body adapt. Skipping increases the chance of side effects severe enough to make you quit entirely, which defeats the purpose.
What if I miss a weekly dose? Within about 48 hours of your scheduled day, take it when you remember and resume your normal schedule. Past 48 hours, skip the missed dose and take the next one on your regular day. Follow your specific program’s guidance if it differs.
How do I know when to step up? Tolerability is the main signal. If you’ve completed four weeks at the current dose and you’re not struggling with significant nausea or other GI symptoms, you’re generally a candidate to move up. If you’re still managing symptoms, hold where you are.
Is 2.4 mg the target for everyone? No. Some patients reach meaningful clinical results at 1.0 mg or 1.7 mg and don’t need to go higher. The right maintenance dose is the one where you’re getting adequate effect with tolerable side effects. That’s a clinical conversation, not a number you pick from a chart.
How long should I stay on the maintenance dose? The STEP-5 data supports continued use for at least two years, and clinical experience extends beyond that. Your maintenance plan should be individualized with your prescribing clinician. Weight regain after discontinuation is well-documented, which is relevant to the “how long” question.
Does compounded semaglutide work the same as Wegovy? The active ingredient is the same. The manufacturing process, regulatory oversight, and evidence base are different (see the section above on supply pathways). Most clinicians expect comparable effects at comparable doses, but the formal clinical trial data was collected on the brand-name product.
Can I switch from brand-name to compounded mid-titration? Yes, as long as you confirm the milligram dose with both programs and there’s no gap in clinical oversight. Don’t assume volume equivalence between different preparations.
References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).
Important Notice
Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.
